TY - JOUR T1 - <em>TGFB1</em> rs8179181 polymorphism is reproducibly associated with Parkinson’s disease in a Spanish population JF - medRxiv DO - 10.1101/2022.07.09.22277447 SP - 2022.07.09.22277447 AU - Alicia Comino AU - Mónica Antolín-Vallespín AU - Azahara López-Benito AU - Gloria Muñoz AU - Francisco Javier del Castillo AU - Lydia Vela AU - Juan Carlos Martínez-Castrillo AU - Amelia Sánchez-Capelo Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/07/11/2022.07.09.22277447.abstract N2 - There is evidence that transforming growth factor (TGF)-β signaling participates in the pathology of Parkinson’s disease (PD). Dampened TGF-β signaling in Smad3- or TβRII-deficient mice leads to the appearance of α-synuclein inclusions in the brain, as well as dopaminergic, motor, and cognitive deficits. Accordingly, we hypothesized that genetic variants of TGFB/SMAD could be risk factors for PD in humans. Here, we present two independent case-control studies aimed at evaluating the association between genetic variants of six genes related to TGF-β signaling (TGFB1, TGFB2, TGFBRI, TGFBRII, SMAD3 and SMAD2) and the development of sporadic PD. A total of 275 unrelated Spanish Caucasian individuals were included in the study (141 cases and 134 controls), with 132 individuals in the discovery phase and 143 individuals in the replication phase. Next-generation sequencing identified a total of 409 variants in the coding, splicing, and untranslated regions of these genes. Analysis of common variants in the discovery phase revealed an association between PD and the TGFB1 rs8179181 variant, which was further confirmed in the replication phase [odds ratio (OR) 0.48, 95% confidence interval (CI) 0.32–0.73, p = 0.00057). A weak association of the SMAD3 rs11556089 polymorphism with PD was also detected (OR 0.49, 95% CI 0.26–0.93, p = 0.0375). Seven haplotypes were identified; however, there were no significant differences in their frequencies between patients with PD and controls. In conclusion, both the discovery and replication phases of this study suggest that the rs8179181 variant of TGFB1 represents a novel susceptibility locus for PD.HIGHLIGHTSDeficient TGF-β signalling via Smad3 induces the formation of α-synuclein aggregates and a parkinsonian pathology in mice.TGFB1, TGFB2, TGFBRI, TGFBRII, SMAD3 and SMAD2 genes were sequenced to search for associations of their allelic variants with idiopathic PD.Two independent case-control studies of Spanish Caucasian individuals identified 409 genetic variants in their coding, splicing and UTR regions.The rs8179181 SNP in TGFB1 was reproducibly associated with idiopathic PD, representing a novel PD susceptibility locus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Instituto de Salud Carlos III - ISCIII (PI16/00186; Plan Estatal de I+D+I 2013-2016) and was co-financed by the European Development Regional Fund 'A way to achieve Europe' (ERDF). The funders played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Hospital Universitario Ramón y Cajal gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsADAlzheimer’s diseaseAFRAfrican populationAIMsancestry informative markersAMRAd-Mixed American populationbpbase pairCIconfidence intervalEASEast Asian populationEUREuropean Caucasian populationGWASgenome-wide association studyHWEHardy-Weinberg equilibriumIBSSpanish populationLBLewy bodyMAFminor allele frequencyNGSnext-generation sequencingORodds ratioPDParkinson’s diseaseSASSouth Asian populationSNsubstantia nigraSNPsingle nucleotide polymorphismSNVsingle nucleotide variationTGF-βtransforming growth factor-betaUTRuntranslated region ER -